Halozyme Therapeutics Inc (HALO)

[Fred Kadiddlehopper]

The patent rolloff for enhanze is not far off but there is a potential lengthening of patent protection both in the US as well as Europe due to the argument that the co-formulation represents a new drug and therefore a new patent, or at least an extension, should be granted. This is being challenged in the courts and, if HALO loses, their income estimate might well be adversely affected. This topic has been a major source of confusion for a long time.